2010
Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia.
Olvey, E., Clauschee, S., & Malone, D. (2010). Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. 87(1). https://doi.org/10.1038/clpt.2009.198
Estimation of the ideal solubility (crystal-liquid fugacity ratio) of organic compounds.
Yalkowsky, S., & Wu, C. (2010). Estimation of the ideal solubility (crystal-liquid fugacity ratio) of organic compounds. 99(3). https://doi.org/10.1002/jps.21897
Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department.
Phan, H., Leder, M., Fishley, M., Moeller, M., & Nahata, M. (2010). Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department. 26(6). https://doi.org/10.1097/PEC.0b013e3181e057e1
Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling.
Conroy, J., Fang, D., Gu, J., Zeitlin, S., Yang, S., Yang, S., VanAlstine, M., Nalwalk, J., Albrecht, P., Mazurkiewicz, J., Snyder-Keller, A., Shan, Z., Zhang, D., Wentland, M., Behr, M., Knapp, S., Bidlack, J., Zuiderveld, O., Leurs, R., … Hough, L. (2010). Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. 13(3). https://doi.org/10.1038/nn.2497
Pharmacotherapeutic disparities: racial, ethnic, and sex variations in medication treatment.
Hall-Lipsy, E., & Chisholm-Burns, M. (2010). Pharmacotherapeutic disparities: racial, ethnic, and sex variations in medication treatment. 67(6). https://doi.org/10.2146/ajhp090161
Prediction of aqueous solubility from SCRATCH.
Jain, P., & Yalkowsky, S. (2010). Prediction of aqueous solubility from SCRATCH. 385(1-2). https://doi.org/10.1016/j.ijpharm.2009.10.003
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α.
Thorne, C., Hanson, J., Schneider, L., Tahinci, E., Orton, D., Cselenyi, C., Jernigan, K., Meyers, K., Hang, B., Waterson, A., Kim, M., Melancon, B., Ghidu, V., Sulikowski, G., LaFleur, B., Salic, A., Lee, J., Miller, A., & Lee, J. (2010). Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. 6(11). https://doi.org/10.1038/nchembio.453
Will the newer oral MS agents be welcomed by managed care organizations?
Lipsy, R. (2010). Will the newer oral MS agents be welcomed by managed care organizations?. 16(8 Suppl).
2009
An exploratory comparison of medication lists at hospital admission with administrative database records.
Warholak, T., McCulloch, M., Baumgart, A., Smith, T., Fink, W., & Fritz, K. (2009). An exploratory comparison of medication lists at hospital admission with administrative database records. 15(9). https://doi.org/10.18553/jmcp.2009.15.9.751
Current and future directions in MS management: key considerations for managed care pharmacists.
Lipsy, R., Schapiro, R., & Prostko, C. (2009). Current and future directions in MS management: key considerations for managed care pharmacists. 15(9 Suppl A).
Pain management principles in the critically ill.
Erstad, B., Puntillo, K., Gilbert, H., Grap, M., Li, X., Medina, J., Mularski, R., Pasero, C., Varkey, B., & Sessler, C. (2009). Pain management principles in the critically ill. 135(4). https://doi.org/10.1378/chest.08-2264
2008
A primer on critical care pharmacy services.
Erstad, B. (2008). A primer on critical care pharmacy services. 42(12). https://doi.org/10.1345/aph.1L375
An evaluation of the validity of inferences made from 3 diabetes assessment instruments: a Rasch analysis.
Handley, L., Jackson, J., & Jackson, J. (2008). An evaluation of the validity of inferences made from 3 diabetes assessment instruments: a Rasch analysis. 4(1). https://doi.org/10.1016/j.sapharm.2007.04.002
Assessing the short-term and long-term burden of illness in cervical cancer.
Lipsy, R. (2008). Assessing the short-term and long-term burden of illness in cervical cancer. 14(6 Suppl 1).
Evaluation of e-prescribing in chain community pharmacy: best-practice recommendations.
Rupp, M., & Warholak, T. (2008). Evaluation of e-prescribing in chain community pharmacy: best-practice recommendations. 48(3). https://doi.org/10.1331/JAPhA.2008.07031
2007
Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice.
Weng, Y., Fang, D., Turesky, R., Behr, M., Kaminsky, L., & Ding, X. (2007). Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. 67(16). https://doi.org/10.1158/0008-5472.CAN-07-1006
Direct observation approach for detecting medication errors and adverse drug events in a pediatric intensive care unit.
Buckley, M., Erstad, B., Kopp, B., Theodorou, A., & Priestley, G. (2007). Direct observation approach for detecting medication errors and adverse drug events in a pediatric intensive care unit. 8(2). https://doi.org/10.1097/01.PCC.0000257038.39434.04
Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions.
Malone, D., Abarca, J., Skrepnek, G., Murphy, J., Armstrong, E., Grizzle, A., Rehfeld, R., & Woosley, R. (2007). Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. 45(5). https://doi.org/10.1097/01.mlr.0000257839.83765.07
2006
Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.
Lee, J., Grace, K., & Taylor, A. (2006). Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. 296(21). https://doi.org/10.1001/jama.296.21.joc60162
Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection.
Kopp, B., Erstad, B., Allen, S., Theodorou, A., & Priestley, G. (2006). Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. 34(2).
2005
Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers.
Dhanasekaran, M., Palian, M., Alves, I., Yeomans, L., Keyari, C., Davis, L., Bilsky, E., Egleton, R., Yamamura, H., Jacobsen, N., Tollin, G., Hruby, V., Porreca, F., & Polt, R. (2005). Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers. 127(15). https://doi.org/10.1021/ja0432158
2004
Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations.
Lipsy, R., Fuller, M., Roski, J., & Mansukani, S. (2004). Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations. 10(3 Suppl). https://doi.org/10.18553/jmcp.2004.10.S3-a.S4
Injectable biologic case studies.
Lipsy, R. (2004). Injectable biologic case studies. 10(3 Suppl).
2003
Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase.
Gu, J., Weng, Y., Zhang, D., Cui, Y., Behr, M., Wu, C., Yang, S., Zhang, D., & Ding, X. (2003). Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. 278(28). https://doi.org/10.1074/jbc.M303125200
2002
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription.
Siddiqui-Jain, A., Grand, C., Bearss, D., & Hurley, L. (2002). Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. 99(18). https://doi.org/10.1073/pnas.182256799
DNA and its associated processes as targets for cancer therapy.
Hurley, L. (2002). DNA and its associated processes as targets for cancer therapy. 2(3). https://doi.org/10.1038/nrc749
Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex.
Kim, M., Vankayalapati, H., Shin-Ya, K., Wierzba, K., & Hurley, L. (2002). Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. 124(10). https://doi.org/10.1021/ja017308q
2001
Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.
Macdonald, K., Brown, M., LaFleur, B., Peterson, K., Lawlor, C., Chen, Q., Packer, R., Cogen, P., & Stephan, D. (2001). Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. 29(2). https://doi.org/10.1038/ng731
2000
Effect of patient information on the quality of pharmacists' drug use review decisions.
Warholak-Juarez, T., Rupp, M., Salazar, F., & Foster, C. (2000). Effect of patient information on the quality of pharmacists’ drug use review decisions. 40(4).
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su, J., Bao, X., Zhang, D., Smith, T., Hong, J., & Ding, X. (2000). Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. 60(18).
Pagination
- First page
- …
- 19
- 20
- 21
- …
- Last page